ENGN
enGene TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case is that detalimogene still shows enough activity and tolerability to support a 2H 2026 BLA filing, with a funded runway into 2H 2028 giving management time to mature the data and execute.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -7.1.
What can break
Analyst and market reaction appears negative after the data, but the packet does not include a verified consensus revision sheet, so sentiment may still be underappreciated or unstable.
Momentum
46
Value
58
Sentiment
79
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.10 · Bull $5.00 · Bear $0.70
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $24.08
Why
Momentum46 · Δ7d +15.0
Value58 · Δ7d +0.3
Sentiment79 · Δ7d -7.1
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
46
34% active weight
Current posture
7d trendImproving
Δ7d
+15.0
Δ21d
+23.3
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.3
Δ21d
+0.8
Sentiment
79
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.1
Δ21d
-47.6
Why this grade
Composite grade B. Momentum 46.2 / Value 58.2 / Sentiment 79.2
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$119.24M
Beta
-0.28
Shares Out
66.98M
P/E (TTM) · Derived
-0.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.90
Rev YoY
-
EPS YoY
-114.1%
Gross Margin
-
Op Margin
-
Net Debt
-$170.41M
Current Ratio
6.30
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology